Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Thierry Facon, MD, Jesús San-Miguel, Saad Z. Usmani, MD, Meletios A. Dimopoulos, MD, Shaji K. Kumar, MD, Maria-Victoria Mateos, Michele Cavo, Bart Heeg, PhD, Sophie Van Beekhuizen, MSc, Marta Pisini, MBA, Sandhya Nair, Annette Lam, BSc, MSc, Mary Slavcev, Jianming He, PhD

Blood (2019) 134 (Supplement_1): 2144.

https://doi.org/10.1182/blood-2019-123561

Published: 2019

Journal Articles

Frailty in Older Adults with Multiple Myeloma: A Study of United States Veterans

Bindiya Patel, MD, Suhong Luo, MPH, Tanya M. Wildes, MD, Kristen M. Sanfilippo, MD MPHS

Blood (2019) 134 (Supplement_1): 3478.

https://doi.org/10.1182/blood-2019-124971

Published: 2019

Journal Articles

Characteristics of Serum Lipidome in Patients with POEMS Syndrome

Hao Zhao, MD, Xue-min Gao, Xinxin Cao, MD, Lu Zhang, MD, Dao-Bin Zhou, Jian Li, MD

Blood (2019) 134 (Supplement_1): 3082.

https://doi.org/10.1182/blood-2019-122239

Published: 2019

Journal Articles

Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group

Kelly D Getz, Lillian Sung, MD PhD, Robert B. Gerbing, Todd A. Alonzo, PhD, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Kasey J Leger, MD MSc, Jessica A. Pollard, MD, Todd M Cooper, DO, Edward Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 331.

https://doi.org/10.1182/blood-2019-131227

Published: 2019

Journal Articles

GFI1-Dependent SGPP1 Repression Promotes Growth and Survival of Myeloma Cells

Daniela Nicoleta Petrusca, PhD, Evgeny Berdyshev, PhD, Colin D. Crean, BS, Judith L Anderson, BS, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4387.

https://doi.org/10.1182/blood-2019-131106

Published: 2019

Journal Articles

Sporadic Late Onset Nemaline Myopathy with a Monoclonal Gammopathy: Comparative Effectiveness of Immuno- and Chemotherapy

David Susman, BMSc, Jesse McLean, PhD, Rouslan Kotchetkov, MD PhD

Blood (2019) 134 (Supplement_1): 5820.

https://doi.org/10.1182/blood-2019-123817

Published: 2019

Journal Articles

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Mark Acosta, PharmD, Arrash Darban, PharmD, MS, Matthew Gitlin, PharmD

Blood (2019) 134 (Supplement_1): 5869.

https://doi.org/10.1182/blood-2019-124990

Published: 2019

Journal Articles

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Sophie Van Beekhuizen, MSc, Timothy J Bell, MHA, Ana Gezin, MSc, Joseph C Cappelleri, PhD MPH, MS, Bart Heeg, PhD, Carl Selya-Hammer, MSc, Majed Charaan, MSc, MBA, Geoffrey Chan, MD

Blood (2019) 134 (Supplement_1): 5846.

https://doi.org/10.1182/blood-2019-125852

Published: 2019

Journal Articles

Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma

Peter Barth, MD, Smith Giri, MBBS, John L. Reagan, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 3155.

https://doi.org/10.1182/blood-2019-121992

Published: 2019

Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 1827.

https://doi.org/10.1182/blood-2019-121658

Published: 2019

Journal Articles

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Kylee L Martens, MD, Parisa R Khalighi, BS, Shan Li, PharmD, Andrew A White, MD, Emily Silgard, MS, Deborah Frieze, PharmD, Elihu H. Estey, MD, David A. Garcia, MD, Sangeeta R Hingorani, MD MPH, Ang Li, MD

Blood (2019) 134 (Supplement_1): 4674.

https://doi.org/10.1182/blood-2019-124058

Published: 2019

Journal Articles

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Gabriel Tremblay, DBA, MSc, BS, Geoffrey Chan, MD

Blood (2018) 132 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2018-99-111931

Published: 2018

Journal Articles

Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Treatment Among Morbidly Obese Patients with Venous Thromboembolism

Alex C. Spyropoulos, MD, Veronica Ashton, MPH, Yen-Wen Chen, Bingcao Wu, Eric D. Peterson

Blood (2018) 132 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2018-99-115144

Published: 2018

Journal Articles

A Feasibility Randomized Trial of Red Cell Transfusion Thresholds in Myelodysplasia

Simon Stanworth, MD, Sally Killick, MD, Zoe McQuilten, MD, Marina Karakantza, MD, Heather Smethurst, RSCN RGN, Laura Pankhurst, M.Sc, Renate L Hodge, B.Sc, M.Sc, Valerie Hopkins, B.Sc, Helen Thomas, M.Sc, Alison J Deary, M.Sc, Rena Buckstein, MD FRCPC, Jeannie Callum, MD, Yulia Lin, MD FRCPC, David Bowen, MD PhD

Blood (2018) 132 (Supplement 1): 527.

https://doi.org/10.1182/blood-2018-99-112949

Published: 2018

Journal Articles

Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data

Regina M Myers, MD, Kelly D Getz, PhD, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Rebecca Citrin, MD, Caitlin W Elgarten, MD, Benjamin L Laskin, MD, Joseph P. Horowitz, Brian T. Fisher, DO, Richard Aplenc, MD PhD

Blood (2018) 132 (Supplement 1): 830.

https://doi.org/10.1182/blood-2018-99-114883

Published: 2018

Journal Articles

Real-World Treatment Patterns and Comparative Effectiveness Among a Population of Elderly Patients with Acute Myeloid Leukemia (AML)

Bruno C. Medeiros, MD, Sacha Satram-Hoang, Faiyaz Momin, Monika Parisi

Blood (2018) 132 (Supplement 1): 835.

https://doi.org/10.1182/blood-2018-99-111267

Published: 2018

Journal Articles

Single-Agent Ibrutinib vs Real-World (RW) Treatments for Patients with Chronic Lymphocytic Leukemia (CLL) and del11q: Adjusted Comparison of RESONATE-2 TM and RESONATE TM with RW Databases

Gilles Andre Salles, MD, Evelyne Callet-Bauchu, Hervé Besson, Margaret Doyle, Jamie Garside, Martin Spacek, Michael Doubek, MD PhD

Blood (2018) 132 (Supplement 1): 4427.

https://doi.org/10.1182/blood-2018-99-112172

Published: 2018

Journal Articles

iNKT Cell Stimulation with Liposomal Alpha/Gal/Cer Amplifies Proliferation of Adoptively Transferred Regulatory T Cells In Vivo and Reduces GvHD

Toshihito Hirai, MD PhD, Federico Simonetta, MD PhD, Kristina Maas-Bauer, MD, Melissa Mavers, MD PhD, Jeanette Baker, Robert S. Negrin, MD

Blood (2018) 132 (Supplement 1): 4519.

https://doi.org/10.1182/blood-2018-99-109836

Published: 2018

Journal Articles

Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma

Gregory Sampang Calip, PharmD, MPH, PhD, Jifang Zhou, MD, Karen Sweiss, PharmD, Pritesh Patel, MD, Alemseged Ayele Asfaw, MSc, B Pharm, Todd Lee, PharmD, PhD, Brian C.-H. Chiu, PhD, Edith A. Nutescu, PharmD., MS, FCCP

Blood (2018) 132 (Supplement 1): 4693.

https://doi.org/10.1182/blood-2018-99-116867

Published: 2018

Journal Articles

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Geoffrey Chan, MD, Gabriel Tremblay, DBA, MSc, BS

Blood (2018) 132 (Supplement 1): 1429.

https://doi.org/10.1182/blood-2018-99-111971

Published: 2018

NARROW

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Frailty in Older Adults with Multiple Myeloma: A Study of United States Veterans

Characteristics of Serum Lipidome in Patients with POEMS Syndrome

Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group

GFI1-Dependent SGPP1 Repression Promotes Growth and Survival of Myeloma Cells

Sporadic Late Onset Nemaline Myopathy with a Monoclonal Gammopathy: Comparative Effectiveness of Immuno- and Chemotherapy

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Treatment Among Morbidly Obese Patients with Venous Thromboembolism

A Feasibility Randomized Trial of Red Cell Transfusion Thresholds in Myelodysplasia

Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data

Real-World Treatment Patterns and Comparative Effectiveness Among a Population of Elderly Patients with Acute Myeloid Leukemia (AML)

Single-Agent Ibrutinib vs Real-World (RW) Treatments for Patients with Chronic Lymphocytic Leukemia (CLL) and del11q: Adjusted Comparison of RESONATE-2 TM and RESONATE TM with RW Databases

iNKT Cell Stimulation with Liposomal Alpha/Gal/Cer Amplifies Proliferation of Adoptively Transferred Regulatory T Cells In Vivo and Reduces GvHD

Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only